Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

Exclusion Criteria

• •More than three previous treatments with PDT or other radiation/laser therapy
• •Previous vitrectomy or other AMD surgical intervention
• •Severe scarring or severe concurrent ocular disease (uncontrolled glaucoma)
• •Patients eligible for the study are randomized into one of two groups. Group 1 receives injections of ranibizumab until retinal edema is resolved. Group 2 receives ranibizumab injections until both retinal edema and the PED are resolved. Study duration is one year with visits once per month.